
Pacific Biosciences of California, Inc.
PACBNASDAQHealthcare● Active
$1.38
$-0.08(-5.17%)
Market Cap$427077321
P/E Ratio—
52W High$2.73
52W Low$0.99
Pacific Biosciences of California, Inc. (PACB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PACB · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.16B | $0.15B | $0.20B | $0.13B | $0.13B |
| Cost of Revenue | $0.11B | $0.12B | $0.15B | $0.08B | $0.07B |
| Gross Profit | $0.05B | $0.04B | $0.05B | $0.05B | $0.06B |
| Gross Margin %(computed) | 31.67% | 24.21% | 26.32% | 38.22% | 45.10% |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.13B | $0.19B | $0.19B | $0.11B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.61B | $0.51B | $0.39B | $0.36B | $0.27B |
| Operating Income | ($0.56B) | ($0.47B) | ($0.33B) | ($0.31B) | ($0.21B) |
| Operating Margin %(computed) | -348.46% | -307.97% | -166.80% | -239.43% | -161.24% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | ($0.55B) | ($0.31B) | ($0.32B) | ($0.31B) | ($0.27B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.01B) | $0.00B | ($0.09B) |
| Net Income | ($0.55B) | ($0.31B) | ($0.31B) | ($0.31B) | ($0.18B) |
| Net Margin %(computed) | -341.47% | -201.18% | -152.97% | -244.92% | -138.85% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.82 | $-1.13 | $-1.21 | $-1.40 | $-0.89 |
| Wtd Avg Shares | 0.30B | 0.27B | 0.25B | 0.22B | 0.20B |
| EBITDA | ($0.03B) | ($0.24B) | ($0.27B) | ($0.28B) | ($0.25B) |
| EBITDA Margin %(computed) | -21.37% | -157.63% | -135.21% | -219.98% | -192.13% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Pacific Biosciences of California, Inc. data
About Pacific Biosciences of California, Inc. (PACB) Income Statement
Pacific Biosciences of California, Inc. (PACB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PACB reported revenue of $0.16B, gross profit of $0.05B (gross margin 31.67%), and net income of ($0.55B) — a net profit margin of -341.47%.
Frequently asked questions
PACB · 4 questionsPacific Biosciences of California, Inc. (PACB) reported revenue of $0.16B for 2025, up 3.9% year-over-year.
PACB revenuePACB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08